SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma’s arm gets Health Canada’s nod for Bevqolva bevacizumab biosimilar

02 May 2026 Evaluate

Aurobindo Pharma’s wholly owned subsidiary -- CuraTeQ Biologics has received Notice of Compliance (NOC) from Health Canada’s Biologics and Radiopharmaceutical Drugs Directorate (BRDD) for Bevqolva, its bevacizumab biosimilar. Health Canada issues an NOC after a successful review, granting formal marketing authorization to the biosimilar by confirming it meets regulatory standards for safety, efficacy, and quality - comparable to the reference biologic drug under the Food and Drug Regulations.

Bevacizumab, a humanized monoclonal antibody, inhibits angiogenesis - the formation of new blood vessels - by blocking vascular endothelial growth factor A (VEGF-A). This action slows tumor vascular growth and treats multiple cancers, including colorectal and lung. Available in 100 mg and 400 mg formulations, the originator product Avastin is marketed by Roche/Genentech.

In 2025, Bevqolva secured marketing authorization from the MHRA and launched commercially for patients across the UK. The product is currently under review by the CHMP with the European Medicines Agency. CuraTeQ Biologics also has two additional biosimilar applications under review by Health Canada.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1389.55 -6.95 (-0.50%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.20
Dr. Reddys Lab 1322.95
Cipla 1309.90
Zydus Lifesciences 891.65
Lupin 2303.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×